Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include ...

Amyloidosis is a complex disease and the program at Huntsman Cancer Institute (HCI) uses a collaborative approach to provide comprehensive medical care. Researchers are tirelessly trying to find new ...

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era Ninety-four patients from ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...

Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment. Cardiac ...

Please provide your email address to receive an email when new articles are posted on . Alnylam announced top-line results of a trial showing that patisiran improved 6-minute walk test distance in ...

Near-complete in vitro TTR stabilization was observed as early as day 28 and through completion of a 30-month study of patients with ATTR-CM. The Food and Drug Administration (FDA) has approved ...

The program, called Alnylam Act ®, provides genetic testing for the diagnosis of acute hepatic porphyria, primary hyperoxaluria type 1 (PH1), and hereditary ATTR (hATTR) amyloidosis. Along with ...

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of ...

Compared with placebo, significant improvement in survival and cardiovascular hospitalization was not observed with anselamimab in the overall patient population. Topline data were announced from a ...